financetom
Business
financetom
/
Business
/
AeroVironment Stock Falls After Q4 Results, EPS Guidance Below Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AeroVironment Stock Falls After Q4 Results, EPS Guidance Below Estimates
Jun 26, 2024 2:10 PM

AeroVironment, Inc. ( AVAV ) shares are trading lower after the company reported its fourth-quarter financial results and issued guidance below estimates Wednesday. Here's a look at the key figures from the report. 

The Details: AeroVironment ( AVAV ) reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 21 cents by 104.76%.

Quarterly sales clocked in at $196.98 million, which beat the analyst consensus estimate of $188.56 million by 4.46% and represents a 5.88% increase over sales of $186.04 million from the same period last year.

AV said revenues reflect higher product sales of $23.1 million, partially offset by a decrease in service revenue of $12.1 million. From a segment standpoint, the year-over-year increase was due to revenue growth in Loitering Munitions Systems of 74%, partially offset by decreases in UnCrewed Systems, the renamed Unmanned Systems segment, of 15% and MacCready Works of 9%.

"AeroVironment ( AVAV ) has yet again delivered exceptional results this past quarter resulting in record revenue and full-year profitability for the company," said Wahid Nawabi, AeroVironment ( AVAV ) CEO.

"We are pleased to also announce our full-year revenue increased 33% from last year's results. Our Loitering Munitions Segment continues to be a key growth driver for our company, and we have expanded capacity to deliver these much-needed systems to keep up with increasing customer demand.”

BTIG analyst Andre Madrid initiated coverage on AeroVironment ( AVAV ) with a Buy rating and a price target of $255 ahead of the print Wednesday.

Outlook:  AeroVironment ( AVAV ) sees fiscal year 2025 earnings per share between $2.61 and $2.92, below the analyst consensus estimate of $3.36 per share, and revenue between $790 million and $820 million, versus the $804.47 million consensus estimate.

AVAV Price Action: According to Benzinga Pro, AeroVironment ( AVAV ) shares are down 7.46% after-hours at $178.43 at the time of publication Wednesday.

Read Also:

• BofA Sees ‘AI With Context And Privacy’ As Apple’s Key To Growth

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tetra Tech Q4 adjusted EPS beats estimates
Tetra Tech Q4 adjusted EPS beats estimates
Nov 12, 2025
Overview * Adjusted EPS for Q4 beats analyst expectations, increasing 29% yr/yr * Company repurchased $50 mln of common stock in Q4 Outlook * Tetra Tech expects fiscal 2026 net revenue between $4.05 bln and $4.25 bln * Tetra Tech sees fiscal 2026 EPS between $1.40 and $1.55 * Company anticipates Q1 fiscal 2026 net revenue between $950 mln and...
Edgewell Personal Care Announces Sale of Feminine Care Business to Essity for $340M
Edgewell Personal Care Announces Sale of Feminine Care Business to Essity for $340M
Nov 12, 2025
Transaction streamlines Edgewell's portfolio and allows the personal care brand to focus on areas of competitive leadership SHELTON, Conn., Nov. 12, 2025 /PRNewswire/ -- Edgewell Personal Care Company ( EPC ) today announced that it has entered into a definitive agreement to sell its feminine care business to Essity, a leading global health and hygiene company based in Sweden,...
MacroGenics Q3 revenue declines, secures $75 mln in partnerships
MacroGenics Q3 revenue declines, secures $75 mln in partnerships
Nov 12, 2025
Overview * MacroGenics ( MGNX ) Q3 revenue declines 34.2% yr/yr * Company secures $75 mln in partnering proceeds from Sanofi and Gilead * MacroGenics ( MGNX ) ends lorigerlimab prostate cancer development, continues ovarian cancer focus Outlook * MacroGenics ( MGNX ) extends cash runway guidance into late 2027 * Company continues development of lorigerlimab in ovarian cancer *...
Merck & Co. Insider Sold Shares Worth $616,395, According to a Recent SEC Filing
Merck & Co. Insider Sold Shares Worth $616,395, According to a Recent SEC Filing
Nov 12, 2025
04:12 PM EST, 11/12/2025 (MT Newswires) -- Cristal N Downing, Chief Communications & Public Affairs Officer, on November 10, 2025, sold 7,085 shares in Merck & Co. ( MRK ) for $616,395. SEC Filing: https://www.sec.gov/Archives/edgar/data/310158/000031015825000061/xslF345X05/form4.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved